Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
The new findings were seen in a small cohort of patients enrolled in phase III studies comparing alemtuzumab with subcutaneous interferon beta-1a (SC IFNB-1a), all of whom had relapsing-remitting multiple sclerosis (RRMS) and were either treatment-naïve at enrolment or had responded inadequately to prior therapy.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
